Evogene (NASDAQ:EVGN) Posts Quarterly Earnings Results, Beats Estimates By $0.78 EPS

Evogene (NASDAQ:EVGN) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.78, Zacks reports. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million during the quarter, compared to analyst estimates of $3.63 million. During the same period last year, the company posted ($1.30) EPS.

Evogene Price Performance

EVGN opened at $1.41 on Friday. The company has a fifty day moving average price of $1.58 and a 200-day moving average price of $2.08. The firm has a market capitalization of $7.57 million, a P/E ratio of -0.32 and a beta of 1.29. Evogene has a one year low of $1.20 and a one year high of $9.90.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Evogene in a research note on Sunday, March 2nd. They issued a “sell” rating for the company.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.